On Oct 24, major Wall Street analysts update their ratings for $Regeneron Pharmaceuticals (REGN.US)$, with price targets ranging from $1,080 to $1,242.
J.P. Morgan analyst Chris Schott maintains with a buy rating, and adjusts the target price from $1,200 to $1,150.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,220 to $1,080.
Evercore analyst Cory Kasimov maintains with a buy rating, and adjusts the target price from $1,250 to $1,175.
TD Cowen analyst Tyler Van Buren maintains with a buy rating, and maintains the target price at $1,230.
Piper Sandler analyst Christopher Raymond maintains with a buy rating, and maintains the target price at $1,242.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
The firm has recalibrated its expectations for Eylea based on the introduction of the Pavblu generic and slightly reduced the projections for Dupixent in the latter half of 2024. Despite this, there's an optimism that the stock might have cleared previous overhangs, presenting a more favorable outlook leading up to imminent catalysts.
Regeneron's inability to obtain a stay against the Eylea biosimilar from Amgen suggests that a launch by Amgen may be forthcoming. Nonetheless, the current weakness in the stock is viewed as a buying opportunity.
Here are the latest investment ratings and price targets for $Regeneron Pharmaceuticals (REGN.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月24日，多家華爾街大行更新了$再生元製藥公司 (REGN.US)$的評級，目標價介於1,080美元至1,242美元。
摩根大通分析師Chris Schott維持買入評級，並將目標價從1,200美元下調至1,150美元。
巴克萊銀行分析師Carter Gould維持買入評級，並將目標價從1,220美元下調至1,080美元。
Evercore分析師Cory Kasimov維持買入評級，並將目標價從1,250美元下調至1,175美元。
TD Cowen分析師Tyler Van Buren維持買入評級，維持目標價1,230美元。
派傑投資分析師Christopher Raymond維持買入評級，維持目標價1,242美元。
此外，綜合報道，$再生元製藥公司 (REGN.US)$近期主要分析師觀點如下：
以下爲今日6位分析師對$再生元製藥公司 (REGN.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
